Resonance Health Limited (ASX: RHT) Secures $6 Million as Liver Fibrosis Breakthrough Opens New Growth Opportunities

Resonance Health Limited (ASX: RHT) is building momentum after reporting promising liver fibrosis trial results and securing commitments for an oversubscribed $6 million capital raising. With revenue growing, profitability restored and cash generation improving, the healthcare technology company is positioning itself to expand beyond its established imaging services. The question is whether its emerging diagnostic technology can deliver meaningful commercial returns.

Key numbers

• $6 million placement: Approximately 83.3 million new shares at 7.2 cents each, representing 14.9% of enlarged issued capital.
• 0.82 AUROC: Preliminary diagnostic accuracy for detecting significant liver fibrosis, based on 50 study participants.
• $15.8 million FY26 revenue: Up 42% from $11.1 million in FY25.
• $2.8 million free cash flow: Up 148% year-on-year, alongside $1.5 million statutory net profit.
• $10.4 million pro forma cash: Including expected net placement proceeds, with projected net cash of $7.9 million.

The latest development

Resonance released preliminary results from its extended proof-of-concept DEVIMLA study on 27 October 2026, evaluating an MRI-based software device designed to detect liver fibrosis without invasive biopsies or additional specialised scanner hardware.

The interim analysis covered 50 of 68 enrolled participants.

For significant fibrosis, the technology achieved an AUROC of 0.82, with 75% sensitivity and 80% specificity.

Advanced fibrosis detection recorded an AUROC of 0.79, although sensitivity declined to 57.9%, highlighting an area requiring further development.

These findings are encouraging but remain preliminary, based on single-site analysis and without independent validation.

The potential commercial opportunity lies in pharmaceutical trials involving obesity, metabolic disease and liver conditions, where reliable fibrosis measurements can support treatment assessment.

Resonance estimates a US$1.3 billion addressable pharmaceutical clinical-trials opportunity, although this is a potential market rather than secured revenue.

What stands out to us

Unlike many emerging medical technology developers, Resonance already operates a profitable, cash-generative business.

FY26 normalised EBITDA increased 83% to $2.6 million, while net operating cash flow reached $2.9 million.

The proposed capital raising would strengthen its balance sheet, although settlement is scheduled for 6 November, with new shares expected to commence trading on 9 November.

At the 3 November closing share price of 7.3 cents, approximately 560.4 million post-placement shares imply an indicative equity value of $40.9 million.

Using projected net cash of $7.9 million, pro forma enterprise value is approximately $33 million, equivalent to 2.1 times FY26 revenue.

That valuation provides an interesting foundation for a profitable healthcare technology business, although sustainable earnings growth remains essential.

The share price was also approximately 49% higher year-to-date, suggesting that expectations have already strengthened.

What the company is doing now

Resonance plans to allocate $1.2 million towards accelerating MRI imaging endpoints, $1.5 million towards expanding its TrialsWest clinical network and $1.5 million towards liver fibrosis validation and regulatory preparation.

Its September strategic alliance with Image Analysis Group also creates opportunities to expand pharmaceutical imaging services.

Management has guided FY27 revenue of $17 million to $22 million and normalised EBITDA of $2.6 million to $3.6 million.

Importantly, this guidance excludes contributions from the investigational fibrosis device, planned new clinical sites, acquisitions and geographic expansion.

These initiatives offer additional growth potential but depend on successful execution.

Insight: Can Resonance Turn Clinical Progress Into Sustainable Earnings?

We think Resonance's strongest advantage is the combination of established pharmaceutical relationships, profitable operations and proprietary medical imaging expertise. Its preliminary fibrosis results strengthen the commercial opportunity, while the proposed placement provides funding to advance development without relying entirely on operating cash flow. However, regulatory clearance remains uncertain, clinical validation is incomplete and additional shares dilute existing ownership. The current valuation appears defensible against established revenue, but a stronger earnings outlook requires evidence that new diagnostic products and expanded clinical services can generate profitable, recurring revenue.

What happens next?

The immediate priorities are completing analysis of all 68 DEVIMLA participants, obtaining feedback from the US FDA and progressing potential investigational-use contracts.

Successful clinical validation and early pharmaceutical customer agreements could strengthen the commercial outlook.

Shareholders should also monitor FY27 margins, cash conversion, TrialsWest expansion costs and renewal of the $2.5 million banking facility maturing in March 2027.

Resonance has established a credible financial foundation and funded growth strategy. Its next challenge is demonstrating that promising diagnostic technology can translate into sustainable revenue and earnings growth.